Telomir Pharmaceuticals, Inc. announced preclinical in vitro data showing Telomir-Zn reduced viable tumor cell counts across multiple human triple-negative breast cancer (TNBC) cell lines, with iron-rescue experiments confirming an iron-dependent mechanism. The Company is completing additional evaluations, preparing a TNBC mouse xenograft study, and anticipates submitting an IND application in Q1 2026.
Key takeaways
Telomir-Zn achieved near-complete tumor cell mortality in MDA-MB-468 (Basal-A / EGFR-high) TNBC model at 72 hours.
Significant partial reduction in viable tumor cells in HCC70 (Basal-like) and MDA-MB-231 (Claudin-low / mesenchymal) TNBC models at 72 hours.
Supplemental iron attenuated Telomir-Zn-induced tumor cell mortality across models.
BT-549 (mesenchymal-like) and HCC1806 (basal-like) TNBC cell lines currently under evaluation.
Prior zebrafish xenograft studies showed statistically significant reductions in tumor growth and metastasis in select TNBC models.
Completed IND-enabling GLP safety and toxicology studies in rats and dogs with no treatment-related adverse toxicity.